DXNVX Accelerates Global Export of Finished Products for Microbiome Brand

DXVX Formulamate-Ofmom (left), DXVX Adjunctive Therapy (right). / Photo by DXVX

DXVX announced on the 25th that the overseas export of its microbiome brand products has been fully underway, driving its growth.

Recently, DXVX signed a contract to export $2.2 million worth of its microbiome-based healthcare products, including 'Formulamate-Ofmom,' to the European Union (EU) region. Export negotiations are also underway with new partners in China, Japan, Southeast Asia, and the Middle East. In particular, its subsidiary Korea Biopharm's factory has completed the FFR (Food Facility Registration) procedure with the U.S. FDA. As these overseas market activities accelerate, high growth in exports is expected. Having received the $3 million Export Tower award on Trade Day last year, DXVX has already surpassed twice that export performance, making another award this year highly anticipated.

DXVX is currently building its own brand malls, Dx&Vx and Ofmom, on major overseas online platforms. By the end of this year, it plans to open its brand malls on global online shopping malls such as Amazon in the U.S., Rakuten and Amazon Japan in Japan, Tmall (Alibaba) and TikTok (Douyin) in China, and Shopee and Lazada in Southeast Asia. It will directly sell its nutrition brand Ofmom series products and 12 DXVX brand products developed and produced by Coriitaly, scheduled to launch in November, to global consumers via B2C alongside direct overseas purchase methods.

A DXVX official stated, “Our company possesses the ‘research-development-production-distribution’ value chain, enabling rapid product development tailored to healthcare market trends by country, and has established specialized global online/offline sales and marketing organizations and networks, giving us competitiveness in expanding global markets. Especially considering the increase in immune product consumption after COVID-19 and the growing global consumer preference for K-healthcare products, along with our current trend of securing global sales networks, we are confident that we will easily achieve this year’s export target of $8 million and set even more aggressive overseas sales goals for 2024, expecting quantum growth.”

Meanwhile, DXVX is collaborating with Coriitaly AAT Research Institute centered on its microbiome research lab to research and develop microbiome-based new drugs, customized healthcare products, and new materials. Recently, through its Chinese subsidiary, it launched basic pharmaceutical antibiotics and officially entered the Chinese maternal and child health market, expanding its lineup and sales network of follow-up basic pharmaceuticals and best-in-class drugs. Aiming to become Asia’s No.1 healthcare company in the first phase, it provides customized healthcare solutions based on microbiome diagnostics for prevention and treatment.

This content was produced with the assistance of AI translation services.